Moreover, Jia et al. (2023) found that ropivacaine suppresses lung cancer cell malignancy by downregulating retinoblastoma-binding protein 4 (RBBP4), suggesting a potential role for ropivacaine in targeting specific molecular pathways involved in tumor progression [42-47]. The gene discussed is RBBP4; the disease is neoplasm.